Cullinan Therapeutics, Inc. Common Stock CGEM
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $36.20 (+189.8% upside)
Key Stats
- Today's Range
- $11.92 – $16.29
- 50-Day Range
- $11.92 – $23.19
- 52-Week Range
- $5.68 – $23.19
- Volume
- 2.21 million shs
- Average Volume
- 958K shs
- Market Cap
- $803.79 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.25
About Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Related Stocks
Compare head-to-head: CGEM vs AMGN·CGEM vs MRNA·CGEM vs HALO·CGEM vs KYMR
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.